Emergent Biosolutions Inc
EBS
Get informed when a big investor buys or sells
+ FollowMarket Cap$249.73M
Close$
$-7.39
264.6% downside
Current Fair Value
264.6% downsideOvervalued by 264.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $249.73 Million |
|---|---|
| Enterprise Value | $706.83 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.98 |
| Beta | 2.34 |
| Outstanding Shares | 51,600,000 |
Return
| Return on Equity | -53.78% |
|---|---|
| Return on Assets | -16.44% |
| Return on Invested Capital | -3.05% |
Valuation & Multiples
| P/E Ratio | -1.41 |
|---|---|
| PEG | -0.1 |
| Price to Sales | 0.32 |
| Price to Book Ratio | 0.75 |
| Enterprise Value to Revenue | 0.92 |
| Enterprise Value to EBIT | -23.33 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.84 |
| Debt to Equity | 1.75 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$-0.09
Average shareholder expectationRevenue Estimate
$177.50 M
Average shareholder expectationNext Earnings Call
Expected Date
October 28, 2026
EPS Estimate
$-0.41
Average shareholder expectationRevenue Estimate
$209.00 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 38.98% |
|---|---|
| Total Calls | 400▼ 99.87% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 26.14%▼ 57.55% |
|---|---|
| Total Invested | $113.68M▼ 68.48% |
| Investors Holding | 68▼ 128.00% |
ESG Score
No data
About Emergent Biosolutions Inc
CEO: Robert Kramer